MEA Multiplex Assays Market

MEA Multiplex Assays Market Size (2023 to 2028)

According to the research report, the Middle East and Africa Multiplex Assays Market size have been valued at USD 0.25 billion in 2023. It is expected to be worth USD 0.35 billion by 2028 and grow at a 6.95% CAGR from 2023 to 2028.

Multiplex Assays are assays used in research to simultaneously measure multiple analytes in a single run. It is different from the procedures that measure only one analysis at a time. For example, they are extensively used in experiments involving functional genomics. These experiments attempted to detect or assay the state of all biomolecules of a given class (e.g., mRNAs, proteins) in a biological sample to determine the effect of an experimental treatment or the impact of a DNA mutation over all of the biomolecules or pathways in the sample.

The increase in R&D activities in the pharmaceutical sector to treat various ailments is expected to be driving the MEA multiplex assays market. These assays are used in clinical trials because they save research costs and manual labor while increasing the efficiency of experiments and medicines. They are also automated, enabling more accessible and faster disease analysis, propelling the Middle East & Africa multiplex assays market.

The use of multiplex tests for cancer diagnosis, the advantages of multiplex assays over single-plex tests, immune system disorders, bone marrow diseases, and other infectious diseases, as well as technological advancements in multiple assay techniques, are further expected to drive the MEA multiplex assays market forward. In addition, with the increased use in manufacturing and the drug research and development process, the pharmaceutical and biotechnology sector dominates the Middle East & Africa multiplex assays market. It is likely to continue to do so over the forecast period.

However, there has been a considerable increase in the demand for healthcare systems worldwide to offer treatments at the lowest possible cost over the last decade. However, whether Therapeutic drug services provide a cost-effective addition to patient care is still a disputed question; this is a significant factor limiting the growth of the Middle East and Africa multiplex assays market.

This research report on the Middle East and Africa Multiplex Assays Market has been segmented and sub-segmented into the following categories:

By Product: 

• Consumable
• Kits & Reagents
• Panels

By Type: 

• Nucleic Acid-Based
• Protein-Based

By Technology: 

• PCR
• Multiplex Array

By Application: 

• R&D
• Companion Diagnostics

By End User: 

• Hospitals
• Clinical Laboratory

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the MEA multiplex assays market is predicted to register for a substantial share in the global market during the forecast period. The presence of the geriatric population and chronic diseases contributes to the market growth during the forecast period. In addition, an increase in clinical trials and increased R&D investments further provide new market growth opportunities in emerging countries. As a result, the significant growth contributors in the region are South Africa, Saudi Arabia, and the United Arab Emirates. 

The multiplex assays market in South Africa dominated the MEA in 2020, and it is likely to continue its dominance throughout the forecast period. The largest market share is attributed to the rising prevalence of chronic diseases such as cancer, the aging population, increased need for targeted and personalized therapy. On the other hand, the presence of well-established healthcare infrastructure, growing awareness, and supportive government policies are uplifting the market growth. 

On the other hand, emerging countries such as Saudi Arabia and UAE are projected to witness promising growth during the forecast period. Increasing investment and funding in healthcare infrastructure development, favorable reimbursement policies, and availability of advanced diagnostics facilities are expected to fuel the growth of the MEA multiplex assays market.  

KEY MARKET PLAYERS:

Companies playing a leading role in the MEA multiplex assays market profiled in the report are the Luminex Corporation, Thermo Fisher Scientific Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Abcam Plc, Becton, Dickinson and Company, Luminex Corporation, Meso Scale Diagnostics, Randox Laboratories Ltd and Seegene Inc.